Dompé’s investigational drug based on the recombinant human nerve growth factor (rhNGF) discovered by Nobel Laureate Professor Rita Levi Montalcini has been granted orphan drug designation by the US FDA for the treatment of retinitis pigmentosa (RP), according to a Dompe spokesperson. This gives new hope for the treatment of this disease for which at present there is no cure. The orphan drug designation comes a few months after orphan drug designation was granted by the European Medicine Agency (EMA).
No comments:
Post a Comment